Search This Blog

Thursday, April 30, 2020

Gilead to be challenged to meet demand for remdesivir

Gilead Sciences (GILD +0.9%) will be hustling to produce sufficient quantities of antiviral remdesivir after the expected nod from regulators after two successful trials in COVID-19 patients.
It started with an inventory of ~5K doses when studies ramped up and now has ~50K which should fly off the shelves as soon as emergency use is authorized. It says its goal is to have “multiple millions” of courses by year-end.
Production is apparently no walk in the park, involving a series of chemical steps, a range of components and manual inspection of each filled vial, the last a labor-intensive step considering the volumes planned. It has been procuring raw materials for some time and has condensed the manufacturing process to 6-8 months from 9-12 months.
Initial quantities will be generally reserved for seriously ill patients.
https://seekingalpha.com/news/3567039-gilead-to-be-challenged-to-meet-demand-for-remdesivir

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.